Characteristics and Outcomes of Patients on Tofacitinib for Alopecia Areata or Rheumatoid Arthritis: A Retrospective Cohort Study

• Asıl Yazarlar: Sarah Choe (Yazar), Abhinav Birda (Yazar), Jesse Salas (Yazar), Olive Anagu (Yazar), Natasha Mesinkovska (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: MDPI AG, 2024-01-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Tofacitinib is a Janus kinase inhibitor (JAKi) that is used off-label for the treatment of alopecia areata (AA). Its boxed warning includes an increased risk of serious adverse events (SAEs) based on the results of a safety trial in rheumatoid arthritis (RA) patients taking the medication. The purpo...